Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

Last updated: September 30, 2021
Sponsor: University of Mississippi Medical Center
Overall Status: Active - Recruiting

Phase

1

Condition

Diabetes And Hypertension

Ulcers

Pressure Ulcer

Treatment

N/A

Clinical Study ID

NCT05076955
2021-UMC014
  • Ages > 18
  • All Genders

Study Summary

Diabetic foot ulcers (DFUs) are a frequent clinical problem observed in diabetic patients. Properly managed, most can be cured, but many patients needlessly undergo amputations because of improper diagnostic and therapeutic approaches. The purpose of this study is to evaluate the effectiveness of a compounded, anti-infective irrigation therapy to increase the healing rates of diabetic foot ulcers and thereby provide a new therapeutic option for health care providers treating high-risk patients with DFUs regardless if secondary fungal infections are present.

Participants diagnosed with diabetes type 1 or 2 and with a documented open diabetic foot ulcer/wound with or without a secondary fungal infection will be included in this prospective, active intervention pilot study. Healing rates will be evaluated every two weeks following the initiation of study therapy up to three months. Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. Participants will be asked to return to clinic every two - four weeks for assessment of the ulcer and compliance with treatment.

A sample size of approximately 100 patients is estimated to have 90% power to detect 15% improvement in ulcer healing rates to 45% and 35% compared to historical benchmarks of approximately 30% for ulcers of <6 months duration and 20% for ulcers ≥6 months duration and/or prior treatment failure, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus
  • An open DFU / wound of any size (including those requiring debridement in operationroom or clinic setting) with or without a secondary fungal infection
  • ≥ 18 years of age
  • Treatment naïve or treatment failure with oral antibiotics to current wound infection

Exclusion

Exclusion Criteria:

  • Patients who present with untreated or on active-treatment for osteomyelitis, exposedbone, or have a life-threatening need of immediate surgery.
  • Patients who are allergic to any components of the investigated product.
  • Patients who have ≥ 15 shoe size
  • Patients who have received IV antibiotics within the past 30 days
  • Patients with HgbA1C > 14
  • Patients on active cancer treatment
  • Patients needing re-vascularization of the affected area but did not receivetreatment.
  • Patients diagnosed with HIV/AIDs
  • Patients unable or unwilling to obtain and wear off-loading footwear

Study Design

Total Participants: 100
Study Start date:
March 31, 2021
Estimated Completion Date:
December 31, 2022

Connect with a study center

  • University of Mississippi Medical Center

    Jackson, Mississippi 39216
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.